Compound News and Research

RSS

Study explores link between BPA exposure and breast cancer

Chronic low-level exposure to a compound found in a variety of plastic household items could pose a threat to women who overproduce a protein linked with breast cancer, say researchers at University of Alabama at Birmingham.

13 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

USPTO issues patent to Rexahn's new anti-cancer arylisoquinolinamine compounds

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent & Trademark Office has issued U.S. Patent No. 8,034,829 to Rexahn, entitled "5, 6, or 7-Substituted-3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof."

13 Oct 2011

NIH awards United Therapeutics $45 million contract to develop potential oral treatment for viruses

The National Institutes of Health (NIH) has awarded United Therapeutics Corporation a contract for up to $45 million over five years "to help develop a potential oral treatment for viruses like influenza and the mosquito-borne tropical fever dengue," the Associated Press/Washington Post reports.

12 Oct 2011

UCLA's screening system can target stem cells responsible for glioblastoma

Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.

12 Oct 2011

UCSF, Anacor to discover and optimize novel oxaboroles as antimalarial drugs

Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.

12 Oct 2011

Boston Therapeutics initiates PAZ320 clinical trial in Type 2 Diabetes

Boston Therapeutics, Inc., a public company registered with the SEC and a developer of diabetes therapeutics, announced today the initiation of its first clinical trial to evaluate the Safety and Efficacy of PAZ320 when added to oral agents or Insulin regimen in Patients with Type 2 Diabetes Mellitus.

12 Oct 2011

Roche's gantenerumab removes amyloid plaques from the brain of patients with AD

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer's disease. The study "Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab" is published today in the October issue of Archives in Neurology.

11 Oct 2011

Unither Virology receives NIAID contract for glycobiology antiviral platform

United Therapeutics Corporation announced that its subsidiary, Unither Virology, LLC, has been awarded a contract for up to approximately $45 million under a Broad Agency Announcement from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for studies directed at the development of a broad-spectrum antiviral drug based on its glycobiology antiviral platform.

10 Oct 2011

Researchers focus on gelatinase inhibitor compounds to treat neurological diseases

Results of a study by a group of University of Notre Dame researchers represent a promising step on the road to developing new drugs for a variety of neurological diseases.

10 Oct 2011

First COX-2-targeted PET imaging agent for use in animal models of inflammation, cancer

A series of novel imaging agents could make it possible to "see" tumors in their earliest stages, before they turn deadly.

10 Oct 2011

BDNF methionine variation increases risk of suicidal behaviour

A new study from the Centre for Addiction and Mental Health has found evidence that a specific gene is linked to suicidal behaviour, adding to our knowledge of the many complex causes of suicide. This research may help doctors one day target the gene in prevention efforts.

10 Oct 2011

BDNF met variation gene linked to suicidal behaviour

7 Oct 2011

NO could improve recovery of critically ill patients in intensive care

The latest results from an expedition to Mount Everest that looked at the body's response to low oxygen levels suggest that drugs or procedures that promote the body's production of a chemical compound called nitric oxide (NO) could improve the recovery of critically ill patients in intensive care.

7 Oct 2011

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.

7 Oct 2011

AMRI announces final results from ALB-127158(a) Phase I clinical studies on obesity

AMRI announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla.

4 Oct 2011

Novel drug shows promise for MLL leukemia

According to British scientists a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia (MLL). MLL is the most common form of leukemia in babies. The study appeared in the journal Nature where scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151.

3 Oct 2011

Perinatal exposure to BPA affects mammary hormone response

A recent study accepted for publication in Molecular Endocrinology, a journal of The Endocrine Society, found that perinatal exposure to environmentally relevant doses of bisphenol A (BPA) alters long-term hormone response and breast development in mice that may increase the propensity to develop cancer.

3 Oct 2011

Galectin posts new corporate video on galectin-inhibiting therapeutics to treat fibrosis and cancer

Galectin Therapeutics Inc. today announced that it posted a new corporate presentation video to its website, www.galectintherapeutics.com, that highlights the Company's leadership position in developing galectin-inhibiting therapeutics to treat fibrosis and cancer.

30 Sep 2011

Circadian files IND with FDA for VGX-100 for the treatment of cancer patients with solid tumors

Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) is extremely proud to announce that its 100% owned subsidiary, Vegenics Pty Ltd, has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate clinical studies of VGX-100. The first trial (Phase I) will involve the treatment of a variety of different cancer types in patients with late stage cancer.

29 Sep 2011